A Phase 3 interventional study of ABC/DTG/3TC and B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 94 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
Drug: B/F/TAF · Drug: ABC/DTG/3TC Placebo
ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
Drug: ABC/DTG/3TC · Drug: B/F/TAF Placebo
At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
Drug: B/F/TAF
600/50/300 mg FDC tablets administered orally once daily without regard to food
Also known as: Triumeq®
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablets administered orally once daily without regard to food
Also known as: Bictegravir (previously referred to as GS-9883)/Emtricitabine/Tenofovir Alafenamide, Biktarvy® [BVY]
Tablets administered orally once daily without regard to food
Tablets administered orally once daily without regard to food
Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Spine Bone Mineral Density (BMD) at Baseline
Time frame: Baseline
Percentage Change From Baseline in Spine BMD at Week 48
Time frame: Baseline; Week 48
Hip Bone Mineral Density at Baseline
Time frame: Baseline
Percentage Change From Baseline in Hip BMD at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in North America, Europe, and Australia. The first participant was screened on 11 November 2015. The last study visit occurred on 23 October 2019.
| Milestone | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Started | 284 | 283 |
| Completed | 265 | 267 |
| Not completed | 19 | 16 |
| Withdrew: Withdrew consent | 4 | 8 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Investigator's discretion | 2 | 0 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Did not receive study drug | 2 | 2 |
| Milestone | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Started | 259 | 265 |
| Completed | 254 | 254 |
| Not completed | 5 | 11 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Investigator's discretion | 1 | 2 |
| Withdrew: Withdrew consent | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
The percentage of participants achieving HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Percentage of Participants With Virologic Failure (HIV-1 RNA ≥ 50 Copies/mL) as Defined by the Modified US FDA-defined Snapshot Algorithm | 1.1 | 0.4 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Defined by the US FDA-defined Snapshot Algorithm | 93.6 | 95.0 |
| cells/µL | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | -31 ± 181.3 | 4 ± 191.0 |
| g/cm^2 | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Spine Bone Mineral Density (BMD) at Baseline | 1.124 ± 0.1833 | 1.103 ± 0.1548 |
| percentage change | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Percentage Change From Baseline in Spine BMD at Week 48 | 0.692 ± 3.1296 | 0.416 ± 2.9973 |
| g/cm^2 | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Hip Bone Mineral Density at Baseline | 1.006 ± 0.1471 | 0.996 ± 0.1363 |
| percentage change | B/F/TAF | ABC/DTG/3TC |
|---|---|---|
| Percentage Change From Baseline in Hip BMD at Week 48 | 0.156 ± 2.2138 | 0.299 ± 2.1077 |
Collected over First dose date up to 169 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind: B/F/TAF | 2/282 (0.7%) | 17/282 (6%) | 122/282 (43.3%) |
| Double-Blind: ABC/DTG/3TC | 0/281 (0%) | 26/281 (9.3%) | 132/281 (47%) |
| Open-label Extension: B/F/TAF From B/F/TAF | 1/259 (0.4%) | 24/259 (9.3%) | 84/259 (32.4%) |
| Open-label Extension: B/F/TAF From ABC/DTG/3TC | 1/265 (0.4%) | 11/265 (4.2%) | 82/265 (30.9%) |
| Event | Double-Blind: B/F/TAF | Double-Blind: ABC/DTG/3TC | Open-label Extension: B/F/TAF From B/F/TAF | Open-label Extension: B/F/TAF From ABC/DTG/3TC |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/282 | 2/281 | 0/259 | 0/265 |
| Abscess limbInfections and infestations | 0/282 | 2/281 | 0/259 | 1/265 |
| Intentional overdoseInjury, poisoning and procedural complications | 2/282 | 0/281 | 0/259 | 0/265 |
| OverdoseInjury, poisoning and procedural complications | 2/282 | 0/281 | 0/259 | 0/265 |
| Suicidal ideationPsychiatric disorders | 2/282 | 1/281 | 0/259 | 0/265 |
| Suicide attemptPsychiatric disorders | 2/282 | 0/281 | 0/259 | 0/265 |
| Acute myocardial infarctionCardiac disorders | 1/282 | 0/281 | 1/259 | 0/265 |
| Abdominal painGastrointestinal disorders | 0/282 | 0/281 | 1/259 | 0/265 |
| DiarrhoeaGastrointestinal disorders | 0/282 | 0/281 | 1/259 | 0/265 |
| Duodenal ulcerGastrointestinal disorders | 0/282 | 0/281 | 1/259 | 0/265 |
| Event | Double-Blind: B/F/TAF | Double-Blind: ABC/DTG/3TC | Open-label Extension: B/F/TAF From B/F/TAF | Open-label Extension: B/F/TAF From ABC/DTG/3TC |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 34/282 | 32/281 | 22/259 | 26/265 |
| DiarrhoeaGastrointestinal disorders | 26/282 | 18/281 | 20/259 | 11/265 |
| NasopharyngitisInfections and infestations | 21/282 | 22/281 | 20/259 | 22/265 |
| HeadacheNervous system disorders | 19/282 | 23/281 | 5/259 | 9/265 |
| InsomniaPsychiatric disorders | 9/282 | 22/281 | 1/259 | 7/265 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/282 | 18/281 | 8/259 | 6/265 |
| NauseaGastrointestinal disorders | 6/282 | 16/281 | 3/259 | 1/265 |
| BronchitisInfections and infestations | 11/282 | 15/281 | 11/259 | 8/265 |
| SinusitisInfections and infestations | 11/282 | 15/281 | 9/259 | 13/265 |
| Back painMusculoskeletal and connective tissue disorders | 13/282 | 13/281 | 13/259 | 6/265 |
The Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.
| Age, Continuous(years) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| Mean | 46 ± 11.1 | 45 ± 11.5 | 45 ± 11.3 |
| Sex: Female, Male(Participants) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| Female | 35 | 29 | 64 |
| Male | 247 | 252 | 499 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 9 | 9 | 18 |
| Black | 59 | 62 | 121 |
| Native Hawaiian or Pacific Islander | 3 | 0 | 3 |
| White | 206 | 202 | 408 |
| Other | 3 | 3 | 6 |
| Not Permitted | 0 | 3 | 3 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| Hispanic or Latino | 46 | 52 | 98 |
| Not Hispanic or Latino | 236 | 227 | 463 |
| Not Permitted | 0 | 2 | 2 |
| Region of Enrollment(Participants) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| Canada | 13 | 22 | 35 |
| Belgium | 1 | 1 | 2 |
| United States | 203 | 198 | 401 |
| Italy | 1 | 1 | 2 |
| United Kingdom | 3 | 3 | 6 |
| France | 4 | 8 | 12 |
| Germany | 17 | 11 | 28 |
| Spain | 31 | 31 | 62 |
| Australia | 9 | 6 | 15 |
| HIV-1 RNA Categories(Participants) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| < 50 copies/mL | 278 | 272 | 550 |
| ≥ 50 copies/mL | 4 | 9 | 13 |
| CD4 Cell Count(cell/µL) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| Mean | 752 ± 302.2 | 694 ± 291.6 | 723 ± 298.1 |
| CD4 Cell Count Category(Participants) | B/F/TAF | ABC/DTG/3TC | Total |
|---|---|---|---|
| ≥ 50 to < 200 cells/μL | 6 | 4 | 10 |
| ≥ 200 to < 350 cells/μL | 16 | 30 | 46 |
| ≥ 350 to < 500 cells/μL | 33 | 42 | 75 |
| ≥ 500 cells/μL | 227 | 205 | 432 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Nov 2015 to primary completion in May 2017, 17 months.
Results were first posted in Jul 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide